About The Study
Atopic dermatitis (eczema) is a chronic condition that causes itchy and dry skin. Eczema is most common in children, but it can occur at any age. It is a long-lasting skin condition that tends to flare at different times. Atopic dermatitis symptoms can appear anywhere on the body and vary widely from person to person. Common symptoms can include dry, cracked skin, inflamed or swollen skin, itchiness, thickened skin, and more. People with atopic dermatitis are at risk of developing allergies, hay fever, asthma, and discolored, scaly skin.
Researchers are looking for adolescents and adults with moderate-to-severe Atopic Dermatitis previously treated with dupilumab (DUPIXENT). The study will investigate the safety and effectiveness of the study drug to reduce the area and severity of eczema symptoms.
To qualify, participants must:
- Be at least 12 years of age
- Have prior treatment with dupilumab and stopped treatement
- Have chronic Atopic Dermatitis (Eczema) that has been present for at least 1 year prior to screening
- Not have had prior treatment with tralokinumab (Adbry)
There is no cost to participate and health insurance is not required to participate. Eligible participants will receive the investigational drug and all study-related assessments and care at no cost. Compensation for time and travel may also be provided.
So far - So good!
To learn more about this study and how you can participate, fill out the form below for a study coordinator to contact you.
Avance Clinical Trials
The sites listed here are not convenient for me.
We're sorry, but you are not eligible at this time...
You can also enter your information below if you would like to be contacted about future clinical research opportunities. Contact your healthcare provider if you have any medical questions. To see if you qualify for a similar study, please click here.